LifeSpan BioSciences, Inc. and MBL International Corporation Announce Multi-Year Licensing and Asset Agreement

For immediate release

LifeSpan BioSciences, Inc. and MBL International Corporation Announce Multi-Year Licensing and Asset Agreement

SEATTLE, WA and Woburn, MA (February 6, 2006)— LifeSpan BioSciences, Inc. ("LifeSpan") and MBL International Corporation ("MBLI"), a wholly owned subsidiary of Medical and Biological Laboratories Co., Ltd. (Nagoya, Japan), announced today a multi-year relationship in which MBLI will distribute antibodies to druggable gene targets that LifeSpan has developed and commercialized. As part of the new relationship, MBLI has purchased LifeSpan’s existing inventory of more than 900 antibodies including the exclusive research reagent sales rights. Financial terms of the transaction were not disclosed.

Dennis Walczewski, chief executive officer of MBLI said, "The relationship with LifeSpan addresses the needs of both organizations. The products and technology obtained from LifeSpan complement our existing product lines, increasing our product offering to over 4,000 products. LifeSpan and MBLI feel that this relationship will help both companies meet the future needs of the scientific research community."

Dr. Joseph Brown, president and CEO of LifeSpan said, "This partnership with MBLI is an important milestone in LifeSpan’s long term strategy to become a global provider of Molecular Pathology products and services, including reagent antibodies to the genes most important in finding new treatments for disease. Moreover, it gives LifeSpan new resources to fund additional development within our core business."

About LifeSpan Biosciences, Inc.
LifeSpan BioSciences, Inc., headquartered in Seattle, Washington, is a privately held company founded in 1995 that employs molecular pathology, bioinformatics, and automated imaging technology to identify and validate targets for its biotechnology and pharmaceutical company customers in Europe, Asia, and North America. Products and services include immunohistochemistry-validated antibodies, custom antibody synthesis, immunohistochemistry contract research services backed by an extensive human tissue bank and GLP capabilities, a human tissue immunohistochemistry localization DrugTarget^TM database, an expression-focused informatics Portal database, the ALIAS^TM automated imaging system, and image analysis software and development.

For additional information on LifeSpan Biosciences, please visit LifeSpan's web site at www.lsbio.com.

About MBL International Corporation
MBL International Corporation of Woburn, Massachusetts is a wholly owned subsidiary of Medical and Biological Laboratories Co., Ltd., a global supplier of Diagnostic and Research Reagents. Medical and Biological Laboratories was founded in Nagoya, Japan over 35 years ago and is listed on the Jasdaq Securities Exchange. Established in 1993 in Massachusetts, MBL International is a leading supplier of high quality products and services to scientific researchers worldwide throughout the academic, government, clinical, biotechnology, and pharmaceutical sectors. MBL International provides essential life science technologies and immunological reagents, including antibodies, ELISA kits, diagnostic kits, and recombinant proteins for disease research and drug discovery in the areas of Apoptosis, Signal Transduction, Autoimmune Diseases, Neurology, Cardiology, Cytokines, Cancer, and Immunology.

For more information on MBL International, please visit the company website at www.mblintl.com.